Previous 10 | Next 10 |
LAUSANNE, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in the upcoming SVB Leerink 10 th Annual Gl...
Finding a treatment that can actually slow the progression of Alzheimer's disease has been referred to as the "holy grail" of drug development.The highway of Alzheimer's drug development is littered with failed candidates that have largely targeted the buildup of beta amyloid, a protein in th...
Shares of AC Immune (NASDAQ: ACIU) jumped 15% on Thursday after the Swiss-based biopharmaceutical company released promising data from its early-stage study of ACI-35.030, an experimental vaccine for the treatment of Alzheimer's disease (AD). AC Immune's vaccine candidate el...
AC Immune (ACIU) announced that its anti-pTau vaccine candidate, a collaboration with Janssen Pharmaceuticals of Johnson & Johnson (JNJ), has generated positive interim results from an ongoing Phase 1b/2a clinical trial involving elderly patients with early Alzheimer’s di...
AC Immune SA (ACIU) +112% as its vaccine generates potent anti-pTau antibody response in a phase 1b/2a study.RCM Technologies, Inc. (RCMT) +92%.Sundial Growers Inc. (SNDL) +48%.MicroVision, Inc. (MVIS) +44% after long range lidar update.Monopar Therapeutics (MNPR) +41% on poten...
Interim results of ACI-35.030 vaccination show high titers of antigen-specific antibodies at potentially therapeutic levels in 100% of older patients with early Alzheimer’s disease ACI-35.030 was safe and well tolerated with no safety concerns observed. Results supp...
LAUSANNE, Switzerland, Feb. 08, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that the first patient has been scanned in a first-in-human study of its...
ATA Creativity Global (AACG) +163%.Anavex Life Sciences (AVXL) +83%.Profire Energy (PFIE) +57%.Theratechnologies (THTX) +56% on FDA fast track designation for the treatment of Sortilin-expressing Cancers.Cyclerion Therapeutics (CYCN) +34%.Atossa Therapeutics (ATOS) +33%.Enservco Corporat...
Highly potent in vivo anti-inflammatory activity demonstrated for novel small molecule NLRP3 inhibitors High-affinity antibodies against extracellular components of the inflammasome pathway show inhibition of target inflammatory responses LAUSANNE, Switzerland, Jan. ...
Mizuho Securities upgrades Eli Lilly ([[LLY]] +4.4%) to buy from neutral rating citing ‘significantly more upside as donanemab adds another important leg to the story.’ The price target is also raised to $222 from $164 per share implying ~16.3% to the previous close.Lilly shares...
News, Short Squeeze, Breakout and More Instantly...
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 Three oral presentations at the Alzheimer’s Association International Conference (AAIC 2024), including talks on morADC, ACI-24.060,...
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...